2024-519071-25-00Not yet recruitingPhase 1
An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jun 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 27 Mar 2025
- Start date
- 1 Mar 2026
- Lead sponsor
- TOLREMO therapeutics AG
- Diseases
- Lung cancer
- EU CT number
- 2024-519071-25-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer (NSCLC). It tests TT125-802 together with adagrasib, osimertinib or docetaxel.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced NSCLC
Main reasons for not taking part
- Healthy volunteers cannot join.
Read by machine on 9 Nov 2026.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Quirónsalud Barcelona | Barcelona | Spain | Not yet recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Not yet recruiting |
| Hospital Universitario Quironsalud Madrid | Pozuelo de Alarcón | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.